Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

The U.S. FDA has approved Revolution Medicines' daraxonrasib (Rasonque), a targeted once-daily pill for adults with metastatic pancreatic cancer who have been previously treated or cannot undergo combination chemotherapy, significantly improving overall survival compared to standard chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.